# Novo says CagriSema delivers greater weight loss than Lilly rival in diabetes trial

https://mins.news/en/item/67426

- Reuters, 2026-09-21 13:45 UTC
- Health
- Original: https://www.reuters.com/business/healthcare-pharmaceuticals/novo-says-its-next-gen-obesity-drug-tops-lilly-rival-late-stage-study-2026-09-21/?link_source=ta_bluesky_link&taid=6ab134e3efcb4f000140094e

> Novo Nordisk said its next-generation experimental drug CagriSema produced an estimated average weight loss of 12.4% among diabetes patients in a late-stage trial, surpassing Eli Lilly’s competing treatment.

## Related coverage

- [Wegovy maker Novo shares slump as management grilled](https://mins.news/en/video/68772) — Reuters, 2026-09-22